01871nas a2200229   4500000000100000008004100001260003100042653001300073653002700086653003400113100001600147700002300163700002300186700002300209700002300232700002300255245007300278856007500351300001200426520118100438020002201619       2027                            d  c2027-01-01bAcademic Press10aancestry10aPopulation descriptors10aPreclinical nonanimal studies1 aErika Moore1 aAlison Veintimilla1 aNana Owusu-Boaitey1 aConnie J. Mulligan1 aCatharine E. Krebs1 aGail A. Van Norman00aChapter 11 - Emphasizing ancestry in human-based biomedical research  uhttps://www.sciencedirect.com/science/article/pii/B9780443265143000047  a177-1883 aSocial and genetic ancestry remain important determinants of human health. Preclinical research and wider society use population descriptors to characterize ancestry. The successful application of these descriptors requires clear, meaningful definitions and awareness of how those performing and evaluating research may use these terms in a biased manner. Ancestry descriptors can be employed together with effective human-based preclinical modeling methods. This encompasses ex vivo studies using cells and other components isolated from patients, in vitro analyses conducted in laboratory settings, and computer-based in silico studies. These preclinical modeling methods improve understanding of the role of ancestry in disease mechanisms, therapeutics, and diagnosis, providing important advantages over animal-based methods. Maximizing the strengths of preclinical modeling and mitigating its limitations may require collaboration between stakeholders such as researchers, research participants, and advocacy groups. Collaboration facilitates preclinical modeling that produces scientifically rigorous results on ancestry in a manner respectful of vulnerable communities.  a978-0-443-26514-3